VITROHM MBS303-B-AX-0RAA Resistor Fixed Single-Through

mbs303 MBS303MSC303 (MBS303 as the intravenous formulation, MSC303 as the subcutaneous formulation) is an innovative CD20CD3 T-cell engager. MBS303 has initiated clinical trials. MBS303 is a CD20×CD3 T-cell-engaging bispecific antibody that has a novel 2:1 (CD20:CD3) confuration to kill malnant B cells. This dose-escalation phase Ⅰ trial

mbs303, MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. The.